Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Ocumension Therapeutics ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 2.66% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -303.35
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 61.21%, its profits have risen by 31.6%
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Ocumension Therapeutics for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Ocumension Therapeutics
-100.0%
0.40
66.22%
Hang Seng Hong Kong
8.25%
0.41
19.93%
Quality key factors
Factor
Value
Sales Growth (5y)
201.12%
EBIT Growth (5y)
2.66%
EBIT to Interest (avg)
-303.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.07
Tax Ratio
0.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.85
EV to EBIT
-20.00
EV to EBITDA
-28.14
EV to Capital Employed
2.06
EV to Sales
14.68
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-10.31%
ROE (Latest)
-7.25%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Technical Movement
15What is working for the Company
OPERATING CASH FLOW(Y)
Highest at HKD -316.14 MM
NET PROFIT(HY)
Higher at HKD -143.47 MM
ROCE(HY)
Highest at -7.71%
NET SALES(Q)
Highest at HKD 315.84 MM
OPERATING PROFIT(Q)
Highest at HKD -68.96 MM
OPERATING PROFIT MARGIN(Q)
Highest at -21.83 %
-3What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 39.75% (YoY
CASH AND EQV(HY)
Lowest at HKD 633.51 MM
DEBT-EQUITY RATIO
(HY)
Highest at -13.55 %
Here's what is working for Ocumension Therapeutics
Operating Cash Flow
Highest at HKD -316.14 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (HKD MM)
Net Sales
Highest at HKD 315.84 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (HKD MM)
Net Sales
At HKD 315.84 MM has Grown at 73.88%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (HKD MM)
Operating Profit
Highest at HKD -68.96 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (HKD MM)
Operating Profit Margin
Highest at -21.83 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Profit
Higher at HKD -143.47 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (HKD MM)
Depreciation
Highest at HKD 75.86 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (HKD MM)
Depreciation
At HKD 75.86 MM has Grown at 31.52%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (HKD MM)
Here's what is not working for Ocumension Therapeutics
Cash and Eqv
Lowest at HKD 633.51 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -13.55 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 39.75% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales






